Robert Califf, FDA commissioner (Tom Williams/CQ Roll Call via AP Images)

Hop­ing to ex­pand mon­key­pox vac­cine sup­ply, US paves the way for new route of ad­min­is­tra­tion

Af­ter mak­ing it clear that the US’ cur­rent mon­key­pox vac­cine sup­ply is in­suf­fi­cient, the FDA on Tues­day au­tho­rized a new route of ad­min­is­tra­tion that should in­crease the num­ber of avail­able dos­es by five-fold.

Reg­u­la­tors cleared Bavar­i­an Nordic’s Jyn­neos vac­cine for in­tra­der­mal in­jec­tion in adults old­er than 18. Un­like sub­cu­ta­neous in­jec­tion — the cur­rent method by which vac­cine is de­liv­ered un­der the skin — an in­tra­der­mal jab goes di­rect­ly in­to the skin. It’s be­lieved that this method re­quires less vac­cine, since the der­mis is rich in den­drit­ic cells which spe­cial­ize in tak­ing up for­eign anti­gens and pre­sent­ing them to the im­mune sys­tem, ac­cord­ing to Daniel Ku­ritzkes, chief of in­fec­tious dis­eases at Brigham and Women’s Hos­pi­tal in Boston.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.